**Spinraza® (nusinersen)**

When requesting Spinraza® (nusinersen), the individual requiring treatment must be diagnosed with an FDA-approved indication and meet the specific coverage guidelines and applicable safety criteria for the covered indication.

**FDA-approved Indication**

Spinraza is indicated for the treatment of spinal muscular atrophy (SMA).

**Coverage Guidelines**

**Treatment of spinal muscular atrophy (SMA)**

An individual must meet **all** of the following criteria for initial approval:

- Has had a genetic test confirming the diagnosis of SMA with bi-allelic mutations in the *survival motor neuron 1 (SMN1)* gene reported as at least one of the following: homozygous deletion, homozygous mutation, or compound heterozygous mutation;
- Has 2 or 3 survival motor neuron 2 (SMN2) gene copies OR has 4 or more SMN2 gene copies with symptoms consistent with Types 1, 2, or 3 SMA;
- Has not received Zolgensma in the past;
- For patients who have received prior treatment with Evrysdi (risdiplam oral solution), further therapy with Evrysdi will be discontinued;
- The following laboratory tests will be evaluated prior to the administration of Spinraza: prothrombin time and/or activated partial thromboplastin time, platelet count, and quantitative spot urine protein test; AND
- Spinraza is prescribed by or in consultation with a physician who specializes in the management of spinal muscular atrophy and/or neuromuscular disorders.

For reauthorization, an individual must meet all of the above **and** the following criteria:

- Has responded to Spinraza therapy (e.g., improvement, achievement, and/or maintenance in motor milestones, reduced need for respiratory support, prevention of permanent assisted ventilation, pulmonary function tests showing improvement, and/or bulbar function test).

**Approval duration (initial): 3 months**

**Approval duration (renewal): 4 months (one dose)**
Dosing Recommendation

Spinraza is administered intrathecally.

The recommended dose is 12 mg (5mL) per administration. Initiate Spinraza treatment with 4 loading doses. The first three loading doses should be administered at 14-day intervals. The 4th loading dose should be administered 30 days after the 3rd dose. A maintenance dose of 12mg should be administered once every 4 months thereafter.

References

6. Evrysdi® oral solution [prescribing information]. South San Francisco, CA; Genentech (a Member of the Roche Group); August 2020.